Josep Maria Peralba

Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Evanthia Galanis, Jan C. Buckner, Matthew J. Maurer et al. · Journal of Clinical Oncology · 2005 · 696 citations · Full text

Pharmacy, Oncology, Pharmacology +15

Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.

Josep Maria Peralba, Linda A. deGraffenried, William E. Friedrichs et al. · PubMed · 2003 · 179 citations

Medicine, Oncology, Pharmacology +17

Design of aging intervention studies: the NIA interventions testing program

Nancy L. Nadon, Randy Strong, Richard A. Miller et al. · AGE · 2008 · 155 citations · Full text

Medicine, Geriatric Medicine, Geriatric Assessment +8

Retinoids, ω‐hydroxyfatty acids and cytotoxic aldehydes as physiological substrates, and H₂‐receptor antagonists as pharmacological inhibitors, of human class IV alcohol dehydrogenase

Abdellah Allali‐Hassani, Josep Maria Peralba, Sı́lvia Martras et al. · FEBS Letters · 1998 · 75 citations

Life Sciences, Biochemistry, Pharmacology +17

Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity

Linda A. deGraffenried, William E. Friedrichs, Letitia C. Fulcher et al. · Annals of Oncology · 2003 · 74 citations · Full text

Medicine, Oncology, Pharmacology +14